Compare ROCK & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROCK | SNDX |
|---|---|---|
| Founded | 1972 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1993 | 2016 |
| Metric | ROCK | SNDX |
|---|---|---|
| Price | $50.86 | $21.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $36.92 |
| AVG Volume (30 Days) | 286.3K | ★ 1.7M |
| Earning Date | 10-30-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $1,383,811,000.00 | $111,304,000.00 |
| Revenue This Year | N/A | $620.14 |
| Revenue Next Year | $6.98 | $115.42 |
| P/E Ratio | $381.94 | ★ N/A |
| Revenue Growth | 23.49 | ★ 595.65 |
| 52 Week Low | $42.86 | $8.58 |
| 52 Week High | $75.08 | $22.73 |
| Indicator | ROCK | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 64.62 |
| Support Level | $48.76 | $19.72 |
| Resistance Level | $51.96 | $22.73 |
| Average True Range (ATR) | 1.57 | 0.91 |
| MACD | 0.45 | -0.05 |
| Stochastic Oscillator | 59.87 | 59.94 |
Gibraltar Industries Inc manufactures and provides products and services for the Renewable energy, Residential, Agtech, and Infrastructure markets. The Renewables Segment is engaged in designing, engineering, manufacturing, and installing solar racking and electrical balance systems. Agtech Segment provides growing and processing solutions including the designing, engineering, manufacturing, full-scope construction, maintenance, and support of greenhouses and indoor growing operations, and botanical extraction systems. It derives key revenue from the Residential segment which offers roof and foundation ventilation products, single point and centralized mail systems electronic package solutions, and Retractable awnings and gutter guards, among other products.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.